NCT02648659

The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients

The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Kyungpook National University Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study assessed the effect of tailored eradication therapy according to Clarithromycin resistance in Helicobacter pylori patients.

Detailed description

This study assessed the effect of tailored eradication therapy according to Clarithromycin resistance in Helicobacter pylori patients. The patients with gastric or duodenal ulcer by endoscopy were registered at the study and inspected Rapid Urease test, Biopsy, IgG-Hp antibody. The tailored eradication therapy was prescribed to patients that confirmed Helicobacter pylori positive in two or more of among the three tests for 14 days. Through this, This study is to assess the effectiveness of eradication rate and to evaluate safety and tolerability of Ilaprazole 10mg qid treatment

Conditions

• Peptic Ulcer

Interventions

Type	Name	Description
DRUG	Ilaprazole	Ilaprazole 10mg 1tablet qid(4 times/day)
DRUG	Amoxicillin	Amoxicillin 500mg 1capsule qid(4times/day)
DRUG	Clarithromycin	Clarithromycin 500mg 1tablet bid(2times/day)
DRUG	Metronidazole	Metronidazole 250mg 2tablets tid(3times/day)

Timeline

• Start date: 2016-03-02
• Primary completion: 2017-01-06
• Completion: 2017-02-14
• First posted: 2016-01-07
• Last updated: 2018-08-09